Vancomycin
Who holds supplier records for Vancomycin? 1 organisation holds a current record for Vancomycin: an active US FDA Type II Drug Master File.
Most records are filed under another form of this substance: Vancomycin Hydrochloride (8 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Vancomycin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/vancomycin
Reading the evidence
- One current record
One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Vancomycin expires 6 Nov 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (1)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Vancomycin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDCompany GMP cert on recordActive DMF 26030 · latest filing May 2012
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (99 listed products contain Vancomycin). The latest listed patent expires 6 Nov 2035. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Vancomycin is a glycopeptide antibiotic used to treat serious bacterial infections by inhibiting bacterial cell wall synthesis. It is particularly effective against Gram-positive bacteria, including resistant strains like MRSA.
Chemical identity
- IUPAC name
- (1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
- Canonical SMILES
- C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
- InChIKey
- MYPYJXKWCTUITO-LYRMYLQWSA-N
- Synonyms
- Vancomycin
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Glycopeptide Antibacterial
- Chemical structure
- Glycopeptides
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Vancomycin?
1 organisation holds an active US FDA Type II Drug Master File or a CEP for Vancomycin: LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Vancomycin Drug Master Files are active?
LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD (DMF 26030). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Vancomycin?
Yes. The latest patent listed for an approved US product containing Vancomycin expires 6 Nov 2035, across 99 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Vancomycin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Vancomycin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.